jm9b01269_si_002.csv (6.75 kB)

Discovery and Characterization of 1H‑1,2,3-Triazole Derivatives as Novel Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy

Download (6.75 kB)
posted on 02.01.2020, 18:34 by Jun-Jie Yang, Wei-Wei Yu, Long-Long Hu, Wen-Juan Liu, Xian-Hua Lin, Wei Wang, Qiansen Zhang, Pei-Li Wang, Shuo-Wen Tang, Xin Wang, Mingyao Liu, Weiqiang Lu, Han-Kun Zhang
The prostanoid EP4 receptor is one of the key receptors associated with inflammatory mediator PGE2-elicited immunosuppression in the tumor microenvironment. Blockade of EP4 signaling to enhance immunity-mediated tumor elimination has recently emerged as a promising strategy for cancer immunotherapy. In our efforts to discover novel subtype-selective EP4 antagonists, we designed and synthesized a class of 1H-1,2,3-triazole-based ligands that display low nanomolar antagonism activity toward the human EP4 receptor and excellent subtype selectivity. The most promising compound 59 exhibits single-digit nanomolar potency in the EP4 calcium flux and cAMP-response element reporter assays and effectively suppresses the expression of multiple immunosuppression-related genes in macrophage cells. On the basis of its favorable ADMET properties, compound 59 was chosen for further in vivo biological evaluation. Oral administration of compound 59 significantly inhibited tumor growth in the mouse CT26 colon carcinoma model accompanied by enhanced infiltration of cytotoxic T lymphocytes in the tumor tissue.